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RESEARCH ARTICLE Open Access
Is treatment-resistant schizophrenia
categorically distinct from treatment-
responsive schizophrenia? a systematic
review
Amy L. Gillespie1*, Ruta Samanaite1, Jonathan Mill2,3, Alice Egerton1 and James H. MacCabe1
Abstract
Background: Schizophrenia is a highly heterogeneous disorder, and around a third of patients are treatment-resistant.
The only evidence-based treatment for these patients is clozapine, an atypical antipsychotic with relatively
weak dopamine antagonism. It is plausible that varying degrees of response to antipsychotics reflect categorically
distinct illness subtypes, which would have significant implications for research and clinical practice. If these subtypes
could be distinguished at illness onset, this could represent a first step towards personalised medicine in psychiatry.
This systematic review investigates whether current evidence supports conceptualising treatment-resistant and
treatment-responsive schizophrenoa as categorically distinct subtypes.
Method: A systematic literature search was conducted, using PubMed, EMBASE, PsycInfo, CINAHL and
OpenGrey databases, to identify all studies which compared treatment-resistant schizophrenia (defined as
either a lack of response to two antipsychotic trials or clozapine prescription) to treatment-responsive
schizophrenia (defined as known response to non-clozapine antipsychotics).
Results: Nineteen studies of moderate quality met inclusion criteria. The most robust findings indicate that
treatment-resistant patients show glutamatergic abnormalities, a lack of dopaminergic abnormalities, and
significant decreases in grey matter compared to treatment-responsive patients. Treatment-resistant patients
were also reported to have higher familial loading; however, no individual gene-association study reported
their findings surviving correction for multiple comparisons.
Conclusions: Tentative evidence supports conceptualising treatment-resistant schizophrenia as a categorically
different illness subtype to treatment-responsive schizophrenia. However, research is limited and confirmation
will require replication and rigorously controlled studies with large sample sizes and prospective study designs.
Keywords: Schizophrenia, Treatment resistance, Treatment refractory, Treatment response, Clozapine, Classification
Background
Schizophrenia is highly heterogeneous and better character-
isation of this heterogeneity is needed to progress research
into aetiology, mechanisms and treatment. While the
majority of patients with schizophrenia respond to typical
or atypical non-clozapine antipsychotics, roughly a third of
patients do not respond well and are considered treatment-
resistant [1]. Differential treatment response represents a
discontinuity which could help divide schizophrenia into
biologically distinct subtypes, as Farooq et al. suggest [2]. If
these subtypes could be distinguished using genetic or
other markers, this would be a significant step towards the
introduction of personalised medicine in schizophrenia
treatment. This paper will review the literature as to
whether treatment-resistant and treatment-responsive
schizophrenia reflect categorically distinct subtypes.
* Correspondence: amy.gillespie@kcl.ac.uk
1Psychosis Studies Department, Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, 16 De Crespigny Park, Denmark Hill,
London SE5 8AF, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gillespie et al. BMC Psychiatry  (2017) 17:12 
DOI 10.1186/s12888-016-1177-y
Treatment-resistant schizophrenia
Evidence suggests that treatment-resistance is a stable
trait, as an early lack of response to treatment has been
consistently shown to predict poor treatment outcome
and diagnosis of treatment-resistance [3–5]. First described
in the 1988 Kane et al. criteria [6], a consistent minimum
requirement for a diagnosis of treatment-resistance is two
periods of treatment with different antipsychotics at
adequate dose (variously defined), each for at least 4 weeks,
without at least a 20% reduction in symptoms. This is
reflected in guidelines for clozapine prescription [7, 8]: a
2014 review of clozapine prescription trends concludes that
clozapine has consistently remained the gold standard for
treatment-resistant schizophrenia, with all evidence-based
guidelines recommending prescription “after failure of two
adequate trials of two different antipsychotic agents” [9].
Recent variations have progressed from exclusively consid-
ering persistent positive symptoms to also incorporating
persistent negative and cognitive symptoms [10, 11]; how-
ever positive symptoms remain a central focus as the main
target of antipsychotics and the primary outcome in the
early clozapine trials which defined treatment-resistance
(see 2016 review highlighting role of positive symptoms
[12]).
The dopamine hypothesis [13] is arguably the most well-
known and well-supported neurochemical model of schizo-
phrenia, but has been unable to explain the occurrence of
treatment-resistant schizophrenia. While clinical response
to antipsychotics is strongly correlated with dopamine re-
ceptor D2 occupancy for most patients, treatment-resistant
patients show no clinical response even when their D2 re-
ceptor occupancy is above the therapeutic threshold [14].
Furthermore, clozapine is found to be highly effective in
treatment-resistant patients [6], despite relatively low levels
of D2 receptor occupancy [15]. It has been suggested that
systematic differences may underlie this differential
response of patients to antipsychotics [16]. In particu-
lar, that the dopamine hypothesis may not apply to
treatment-resistant schizophrenia [17], where symptoms
are instead driven by non-dopaminergic abnormalities,
perhaps involving the glutamate system [18–20].
Burden of treatment-resistance
Approximately a third of patients are treatment-resistant
[1, 8], though some estimates are as high as 40–60% [21,
22]. Among mental illness, treatment-resistant schizo-
phrenia is associated with some of the highest levels of
impaired functioning [23], rates of hospitalisation [24],
and costs to society, with one review estimating that
treatment-resistance leads to an additional $34 billion in
direct healthcare costs in the United States alone [25].
As Farooq et al. comment [2], classifying schizophre-
nia by treatment-response helps ensure that treatment-
resistance remains a priority; they propose establishing
clinical criteria that distinguishes these groups and then
evaluating the endophenotypes and biomarkers present
in these samples. Previous reviews have looked at predic-
tors of treatment-response in schizophrenia [16], but we
are unaware of any reviews that have focused exclusively
on studies comparing patients with treatment-resistance
(defined as above by two failed antipsychotic trials)
against known treatment-responders. Therefore, we con-
ducted a systematic review of all studies which compare
treatment-resistant versus treatment-responsive patients
with schizophrenia to investigate whether current evi-
dence supports a conceptualisation of these as categoric-
ally distinct subtypes.
Method
Inclusion/exclusion criteria
Our inclusion criteria were: original data comparing pa-
tients with treatment-resistant and treatment-responsive
schizophrenia; all patients have a primary diagnosis of
schizophrenia or schizoaffective disorder; the definition
of treatment-resistance incorporates (as a minimum)
two failed antipsychotic trials; the treatment-responsive
group comprises of patients with a known response to
non-clozapine antipsychotics; publication in a peer-
reviewed journal.
Studies were excluded if: treatment-resistance was clas-
sified based on only one antipsychotic trial; treatment-
responsiveness was defined solely as not meeting
treatment-resistant criteria; the group labelled “treatment-
responsive” included patients on clozapine; if studies of
clinical variables were cross-sectional (as treatment-
resistance is defined by current clinical state).
Search strategy
The databases searched were: Ovid (on 25th January 2015,
including Medline, Embase, PsycInfo and PsycArticle),
PubMed (on 2nd February 2015) and CINAHL (on 2nd
February 2015). The grey literature database OpenGrey
was also searched on 2nd February 2015. Search terms
included synonyms for schizophrenia and treatment-
resistance (Additional file 1). Relevant review articles and
conference proceedings published between 2005 and 2015
were identified and reference and abstract listings were
screened. All eligible studies were forward and backward
screened. At the stage of full-text screening, the two jour-
nals with the highest number of potentially eligible publi-
cations were Biological Psychiatry and Schizophrenia
Research; therefore, the tables of contents for all online
volumes of these journals were hand-searched. Authors of
all eligible studies were contacted requesting any other
eligible findings, published or unpublished.
All identified studies underwent title and abstract screen-
ing, then all potentially eligible studies underwent full-text
screening. When full-text articles were not available or
Gillespie et al. BMC Psychiatry  (2017) 17:12 Page 2 of 14
eligibility was unclear, authors were contacted where pos-
sible. If confirmation of eligibility was not possible, studies
were excluded. AG did the initial screening, then RS inde-
pendently re-screened a randomly selected a) 10% of titles
and abstracts identified by the database search and b) 20%
of full-text articles identified by title and abstract screening.
Cohen’s kappa was calculated to provide a conservative
measure of inter-rater reliability; this produced kappas of
0.8 and 1 respectively, indicating substantial agreement. If
the second reviewer identified novel potentially eligible
studies, these were re-screened collaboratively.
A standard data extraction form was used (Additional
file 1). If the treatment-resistant group were sub-divided
by clozapine response, the data from both the clozapine-
responsive and clozapine-nonresponsive (known as ultra-
treatment resistant) group were reported.
Quality assessment
To assess study quality and risk of bias, the Newcastle-
Ottawa Scale for case-control studies was adapted (Add-
itional file 1), as has been done previously [26]. The scale
was adapted in advance to suit the scope of the research
question, to include items on statistical analysis and
sample size, and to allow for more differentiation
between studies. Studies were scored out of 5 for selec-
tion of participants, out of 2 for comparability and out
of 4 for predictor ascertainment and analysis. A total
score of 9 or above was deemed high quality, a score of
6–8 was deemed moderate quality, and below 5 was
deemed low quality. Low quality studies were then ex-
cluded from the review.
This systematic review has been conducted and re-
ported according to PRISMA principles and guidelines,
to aid evaluation and utilisation (see Additional file 2:
PRISMA checklist).
Results
From 5215 unique studies identified by the database
search, 19 papers met inclusion criteria. 4 more eligible
studies were identified through further screening methods
outlined above. 4 were excluded due to low quality scores.
(See Fig. 1 for flowchart and Additional file 1 for excluded
studies table).
Overall, 19 studies are included in this review (Add-
itional file 1). Two studies had an overlap in partici-
pants but report on different variables.1 The average
quality assessment score (Additional file 1) was 6.9
(range 6–8), moderate: 3.2 for selection, 0.3 for
comparability and 3.4 for predictors. There were no
studies with a high quality score; as low quality
studies were excluded, this means all studies were of
moderate quality. Definitions for treatment-resistance
and response varied considerably, as shown in Tables 1
and 2.
Neuroimaging
There were five neuroimaging studies covering magnetic
resonance imaging (MRI), electroencephalography (EEG),
positron-emission tomography (PET), and magnetic reson-
ance spectroscopy (MRS). All report controlling for basic
demographics like age and sex but only three [17, 18, 27]
report controlling for other confounders such as ethnicity,
weight and smoking.
Two investigated brain volume, measured by MRI. In a
study of 37 New Zealand patients (19 resistant, 18 respon-
sive), Anderson et al. reported significantly lower grey
matter volumes, especially in cortical areas, for treatment-
resistant patients, but no differences in whole brain or
white matter volume [28]. Ultra-treatment resistant pa-
tients also showed significantly lower grey matter volume
than treatment-responsive patients, with numerically larger
deficits than treatment-resistant patients (though this differ-
ence was not significant). Compared to healthy volunteers,
treatment-responsive patients did not significantly differ in
grey matter volume, while treatment-resistant patients
showed significantly lower volumes. All the treatment-
resistant patients were prescribed clozapine, while the
majority of treatment-responsive patients were prescribed
olanzapine or risperidone. In Molina et al., 49 Spanish
patients (30 resistant, 19 responsive) were studied [29]; no
patients had taken clozapine prior to baseline assessments,
and all patients were trialled on haloperidol to confirm
resistance or responsiveness. They report that discriminant
analysis demonstrated hypertrophy in occipital white mat-
ter to be the best predictor of treatment-resistance, and that
significant decreases in frontal and occipital grey matter of
treatment-resistant patients compared to healthy volunteers
were not evident in treatment-responsive patients.
In the same study, Molina et al. also investigated P300
parameters - the late component of the event-related
potential - with EEG but found no differences between
responsive and resistant patients [29].
One study compared striatal dopamine synthesis capacity
with PET measurement of [18 F]-DOPA uptake, in a
matched-design study of 24 British patients (12 resistant,
12 responsive) [17]. No participants were prescribed cloza-
pine at the time of scanning (though two treatment-
resistant patients had been previously prescribed clozapine
but experienced adverse reactions); the majority of patients
in both groups were prescribed olanzapine or risperidone
depot. They reported (with multiple testing correction)
significantly lower dopamine synthesis capacity in treatment-
resistant patients compared to treatment-responsive patients,
in the whole striatum; and in the associative and limbic,
but not sensorimotor, striatal subdivisions. Compared to
healthy volunteers, treatment-resistant patients were not
significantly different, unlike treatment-responsive pa-
tients who showed significantly higher dopamine synthesis
capacity than healthy volunteers.
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Two studies measured regional brain metabolite concen-
trations using MRS. Demjaha et al. [18] carried out a study
of 14 patients (6 resistant, 8 responsive) and found that
treatment-responders had significantly lower levels of N-
acetyl aspartate (NAA) in the anterior cingulate cortex
(ACC) than both treatment-resistant patients and healthy
volunteers. Also, while ACC glutamate levels in treatment-
resistant patients compared to treatment-responsive
patients were not significantly different, treatment-
resistant patients had significantly elevated ACC
glutamate levels compared to healthy volunteers, while
treatment-responsive patients did not. Medication sta-
tus or history was not reported. Goldstein et al. [27]
performed a MRS study in 31 New Zealand patients
(16 resistant, 15 responsive), acquiring data in the
putamen, dorsolateral prefrontal cortex (DLPFC) and
ACC. In contrast to Demjaha et al., they found no
group differences in glutamate, NAA or choline. How-
ever, they did find patients with treatment-resistant
schizophrenia had significantly higher total glutamate
+ glutamine (Glx) in the putamen (with family-wise
error correction) than both treatment-responsive and
ultra-treatment resistant patients. There was no
significant difference between healthy volunteers and
treatment-resistant patients, but healthy volunteers
appeared to have very similar levels to the two other
patient groups. Also, ultra-treatment resistant patients
had significantly lower Glx in the DLPFC than treatment-
responsive patients, with treatment-resistant patients and
healthy volunteers showing levels in between. All their
treatment-resistant patients were prescribed and respon-
sive to clozapine, while all treatment-responsive patients
were prescribed non-clozapine atypical antipsychotics
(with the majority prescribed olanzapine and risperidone).
Gene-association
There were nine gene-association studies, with no eligible
genome-wide association study (GWAS) papers. All of
them used white participants.
Two investigated polymorphisms in the brain-
derived neurotrophic factor (BDNF) gene. In a study
of 94 Finnish patients (51 resistant, 43 responsive), no
group differences were found for the G169A poly-
morphism (Val66Met) or the C270T polymorphism
[30]. In a study of 88 French patients (20 resistant, 68
responsive), treatment-resistant patients displayed
significantly fewer long alleles of the BDNF dinucleo-
tide repeat polymorphism than treatment-responsive
patients [31].
Two studied the serotonin 2A receptor (5-HT2A)
gene, specifically the T102C polymorphism. In a study of
102 Canadian patients (63 resistant, 39 responsive), a
Fig. 1 Flowchart of identified, included and excluded studies
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significantly higher frequency of the C/C genotype in
treatment-resistant patients was reported [32] and a
study of 94 Finnish patients (51 resistant, 43 responsive)
replicated this association, but only in females [33].
The latter also reported a significantly higher frequency
of the C/A genotype for the tryptophan hydroxylase
enzyme (TPH1) gene in treatment-resistant patients, but
no group differences for the guanine-nucleotide-binding
protein (GNB3) gene [33].
In a study of 193 French patients (45 resistant, 148
responsive) considering the 5’UTR (ccG repeat) polymorph-
ism of the reelin gene, a significantly higher frequency of
ccG10 alleles in treatment-resistant patients was found [34].
Another study investigated the regulator of g-protein
signalling (RGS4) gene in a study of 93 Finnish patients
(50 resistant, 43 responsive), but found no group differ-
ences [35].
The dopamine receptor 3 (DRD3) gene, specifically
the Bal I polymorphism, was examined in a study of 89
French patients (19 resistant, 70 responsive) which
reported significantly less homozygosity for treatment-
resistant patients [36].
A study of 38 Finnish patients (19 resistant, 19 responsive)
investigated the human leukocyte antigen (HLA) genotypes
and found significantly higher HLA-A1 allele frequency for
treatment-resistant patients [37]. In contrast, a study of 88
Table 1 Definitions of treatment-resistance
Study Chlorpromazine
dose and trial
length
Number
of trials
necessary
Minimum
length of
illness
Minimum
severity
score
Specify
symptoms
Clozapine
prescription
Responsive
to clozapine
Inability to live
independently
Prospective
confirmation
28 “Therapeutic
doses”
6 weeks
2 x
29 “Adequate”
8 weeks
2 CGI≥ 4 >4 on 1+ specified
PANSS item
17 400–600
4–6 weeks
2 5 years BPRS > 45 >4 on 2+ specified
BPRS items
x
18 400–600
4–6 weeks
2 5 years BPRS > 45 >4 on 2+ specified
BPRS items
x
27 NICE algorithm CGI < 4 x
30 400 mg
4 weeks
2 CGI > 4 One of specified
BPRS items
33 400 mg
4 weeks
2 CGI≥ 4 One of specified
BPRS items
x
34 “sufficient
duration”
“several” May score
5–7
x
32 “optimal clinical
requirements”
3 Continuous
for 2 years
x
35 400 mg
4 weeks
2 CGI≥ 4 One of specified
BPRS items
x
36 “sufficient
duration”
“several” x
31 “sufficient
duration”
“several” x
37 1000 mg
6 weeks
3 BPRS > 45
CGI > 4
>4 on 2+ specified
BPRS items
x x
38 1000 mg
8 weeks
3
39 750 mg
6 weeks
3 Continuous
for 2 years
GAS < 40 x
40 4–6 weeks 2 <30% decrease
in PANSS
41 Kane criteria inclusive inclusive
42 Therapeutic
doses
6 weeks
2
43 750 mg
6 weeks
3 2 years BPRS > 45
CGI > 4
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Israeli patients (50 resistant, 38 responsive) conducted HLA
typing and found no group difference in frequencies of
different classes of antigens [38]. All treatment-resistant pa-
tients were prescribed clozapine, while all treatment-
responsive patients were prescribed haloperidol.
Unfortunately, none of these findings are reported to
survive multiple-testing correction: four do not report
correction [31, 33, 34, 36] and two report their findings
becoming non-significant after correction [32, 37].
Genetic loading
There was one study of familial genetic loading and preva-
lence in relatives, which studied the prevalence of schizo-
phrenia spectrum disorders, cluster A personality disorders
and long-term psychiatric care in relatives, and calculated
family loading scores and morbidity risks [39]. In a study of
71 Canadian patients (35 resistant, 36 responsive), first and
second degree relatives of treatment-resistant patients had a
significantly higher morbidity risk of schizophrenia
spectrum disorders compared to relatives of treatment-
responsive patients, and a significantly higher familial-
loading score was found for treatment-resistant patients.
While treatment-resistant patients demonstrated signifi-
cantly greater risk than healthy volunteers, treatment-
responsive patients did not differ significantly. No group
differences were found for risk of cluster A personality
disorders or long-term psychiatric care in relatives.
Clinical variables
Two studies investigated whether clinical variables were
associated with subsequent treatment response or
resistance.
Table 2 Definitions of treatment-responsiveness
Study Consistent good
response to
antipsychotics
Remission
allowing
discharge
Remission
sustained over
long period
Minimum
severity before
treatment
Minimum
improvement
Maximum
severity after
treatment
Relapse when
medication
discontinued
Prospective
confirmation
Other
28 >50% decrease
in BPRS/PANSS
29 x
17 6 months x ≤3 PANSS item scores;
≤3 BPRS item scores;
≤2 SAPS/SANS item
scores
18 6 months x ≤3 PANSS item scores;
≤3 BPRS item scores;
≤2 SAPS/SANS item
scores
27 At most mildly ill (CGI)
30 x CGI > 4
33 x CGI > 4 No psychotic symptoms
34 x May score 1–4
32 x at least 1
admission
“full or partial
remission”
35 x CGI > 4 No psychotic symptoms
36 x
31 x
37 20% decrease
in BPRS total
CGI rating ≤3 or
BPRS score≤ 35
38 x CGI rating of
“very/much
improved”
12 weeks
haloperidol
< 30 mg
39 x at least 1
admission
“full or partial
remission”
CGI rating ≤3 or
BPRS score≤ 30
x x
40 >30% decrease
in PANSS
x
41 “at most mild”
42 x
43 x at least 1
admission
BPRS score≤ 30
CGI rating <3
x
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There was one prospective study [40] of Positive and
Negative Syndrome Scale (PANSS) scores2 in which
patients with no previous regular antipsychotic use and an
illness onset within the last five years were randomised to
receive either first or second generation non-clozapine
antipsychotics in an open trial. Those that did not respond
after one trial were then switched to another anti-
psychotic, and those that failed two trials were deemed
treatment-resistant (4 patients in total). In the study of 17
Brazilian patients, treatment-resistance at twelve weeks
was predicted by lower baseline total PANSS score. This
study also measured improvement in the first 2 weeks of
antipsychotic treatment and did not find this to be pre-
dictive of treatment-resistance.
Meltzer et al. studied age of onset [41]. In a study of
322 American patients (196 resistant, 126 responsive),
treatment-resistant patients had an earlier age of onset.
Neurocognitive function
There were two papers looking at neurocognitive function.
Joober et al. examined 75 Canadian patients (39 resistant,
36 responsive) [42]. Treatment-resistant patients had greater
deficits in verbal ability and language, verbal memory and
learning, and visual memory, but there were no significant
differences for visual-spatial ability, abstraction and concept
formation, visual motor processing and sustained attention.
Treatment-resistant patients were prescribed a combin-
ation of typical and atypical antipsychotics (including
clozapine), while all but four treatment-responsive
patients were prescribed typical antipsychotics.
De Bartolomeis et al. investigated verbal memory,
working memory, motor speed, verbal fluency, pro-
cessing speed and executive functions, in a study of 41
Italian patients (19 resistant, 22 responsive) [43]. The
only significant difference reported was lower verbal
memory scores in treatment-resistant patients. Medi-
cation status or history separated by group is not re-
ported but prescription of first and second-generation
antipsychotics was not significantly different between
treatment-resistant and responsive patients.
Demographic characteristics
There was one study measuring demographic charac-
teristics. Meltzer et al.– described above - studied
gender and ethnicity [41]. The study demonstrated a
significantly higher frequency of white patients in the
treatment-resistant group compared to treatment-
responsive, but no gender difference.
Discussion
Strengths and weaknesses
This is the first systematic review directly addressing
whether treatment-resistant schizophrenia is categorically
different from treatment-responsive schizophrenia, a
question with substantial implications for research and
clinical practice. It is somewhat unusual for a systematic
review to address a theoretical question like this, but the
benefits of comprehensiveness, reduced bias, and replic-
ability remain desirable. To ensure that findings were not
biased towards research fields that unduly influenced the
conclusions, a broader search strategy than is conven-
tional was necessary. This provides a comprehensive over-
view allowing the emergence of a pattern across research
fields. It also highlights the areas lacking in quantity or
quality of research. Another strength of this review is the
focused definitions of treatment-resistance and treatment-
responsiveness; they relate to clinical practice for diagnos-
ing and treating treatment-resistance and provide a com-
parison between two groups of patients with distinctly
different responses to antipsychotics.
However, this study does have limitations. Firstly,
while every effort was made to seek out all available re-
search there is a stronger chance of publication bias for
non-RCT studies, as there are less protective measures
(such as prospective registration of trials) in place; how-
ever, we did identify several studies reporting null findings
(e.g., 4 out of 9 gene-association studies reported null
results). Secondly, despite not excluding non-English
language papers, papers were largely Western and partici-
pants were largely white. Thirdly, significant heterogeneity
remained in definitions of treatment-resistance and
treatment-responsiveness and in the populations and
methods used to recruit participants, making comparison
different. Fourthly, in comparing based on treatment out-
come, antipsychotic response and resistance are not readily
separable from group differences in illness symptomatology
or severity. Also, the binary comparison of treatment-
resistant patients to confirmed treatment-responders argu-
ably ignores some of the complexity of the disorder. Not
only can treatment-response be considered along a
spectrum [44], but schizophrenia is heterogenous in more
than just treatment-outcome and likely encompasses a
spectrum of disorders [45]. However, focusing on this com-
parison of patient groups with distinctly different responses
to antipsychotics is a strong starting point for addressing
the heterogeneity, one likely to provide larger effect sizes
and one which provides information with significant clinical
relevance. Finally, the strict definitions of treatment-
resistant and treatment-responsive patients mean that
potentially relevant studies investigating markers of
treatment-resistance using different definitions have been
excluded. The rest of the discussion incorporates particu-
larly pertinent studies from this broader literature.
Neurotransmission
Dopamine system
Two studies identified in this review indicate that
treatment-resistant schizophrenia may be differentiated
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from treatment-responsive schizophrenia by measures of
dopaminergic function: specifically, lower levels of striatal
dopamine synthesis capacity, equivalent to levels in
healthy volunteers [17], and less homozygosity of the
DRD3 allele [36]. As the dopamine synthesis study was
cross-sectional, the group difference may reflect differ-
ences in medication history or other extraneous group dif-
ferences. However, the finding of lower dopamine
synthesis in treatment-resistant patients is consistent with
evidence that elevated levels of baseline synaptic dopa-
mine and plasma levels of homovanilic acid (HVA) – a
metabolite of dopamine - predict good treatment response
[46, 47] (these studies were not included in our review as
they looked at response to a single antipsychotic trial).
This finding also aligns with two relevant reviews: one re-
view of predictors of antipsychotic response (primarily cit-
ing studies of single antipsychotic trials) that concluded
HVA was the most predictive peripheral marker [16], and
one systematic review of neuroimaging findings in resist-
ant and responsive patients with schizophrenia (without
our strict definitions of these groups) which highlighted
reduced striatal dopamine synthesis as one of five features
of treatment-resistant schizophrenia [48].
If these findings reflect that treatment-resistant patients
lack the striatal dopaminergic elevations typically detected
in schizophrenia, this could explain why treatment-
resistant patients show little response to D2 dopamine
receptor blockade with conventional antipsychotic treat-
ment [14]. This would implicate categorical differences
between the two patient groups – one displaying normal
dopamine function and one displaying abnormalities – ra-
ther than a difference of severity, and this is also the
conclusion of another systematic review [48].
Serotonin system
The studies identified report that treatment-resistance
may be differentiated from treatment-responsive schizo-
phrenia by predominance of the C allele of the T102C
polymorphism of the 5HT2A gene (encoding the main
excitatory serotonin receptors) [32, 33] and predomin-
ance of the C/A genotype for the A779C of the TPH1
gene (encoding the enzyme that catalyses the conversion
of tryptophan to 5-HTP, serotonin’s precursor) [33].
Genetic abnormalities driving a categorically different
pattern of serotonin function in treatment-resistant pa-
tients would be consistent with the fact that clozapine is
a potent 5-HT2A receptor antagonist [49]. However,
while the 5HT2A association was the only replicated
gene-association finding in our review, neither study
survived multiple-testing correction and reviews on
T102C and treatment-response find largely null results
[16]. Also, the A779C polymorphism has been associated
with nicotine dependence creating a possible confounder
[50].
Nonetheless, other studies (not included in our review
as they looked at response to only one antipsychotic trial)
have found that lower 5-HT plasma levels, as well as a
subsequent increase during treatment, predict poorer
response to atypical antipsychotics, with responders
showing equivalent levels to healthy volunteers [51].
Similarly, those who respond to D-fenfluramine (which
enhances serotonin transmission) with greater sero-
tonin release have been shown to respond poorly to
subsequent antipsychotic treatment [52].
Glutamate system
The identified studies indicate that treatment-resistance
may be differentiated by abnormalities in brain glutamate
concentrations not seen in treatment-responsive patients;
as with the dopamine findings, this again suggests a
categorical difference rather than one of severity. A study
by our group found higher levels of glutamate in the ACC
in treatment-resistant but not treatment-responsive pa-
tients compared to healthy volunteers [18]. We have
recently (published after the searches in this review were
conducted) reported elevated ACC glutamate in resistant
compared to responsive patients in a separate sample [20],
and the results are also consistent with a study in first-
episode patients showing that those patients who respond
poorly to treatment have elevated ACC glutamate levels
compared to those who respond well [19]. Together these
studies suggest that elevated ACC glutamate may associ-
ate with poor antipsychotic response. However, Goldstein
et al. [27], found no group differences in glutamate in the
ACC, although glutamate plus glutamine (Glx) was ele-
vated in the putamen in the treatment-resistant compared
to responsive group, with the responsive group appearing
equivalent to healthy volunteers. When subdividing within
treatment-resistant patients this elevated Glx was specific
to those who responded to clozapine, and not demon-
strated in ultra-treatment resistant patients, suggesting a
role in clozapine’s efficacy.
Other reviews of neuroimaging studies of treatment-
resistance have differed in their interpretation of this
literature, with a shift towards confidence that gluta-
matergic differences exist. One 2015 review [53] re-
ported the Demjaha et al. findings but concluded there
were no consistent findings in the field, whereas the
2016 Mouchlianitis et al. review [48] reported both
papers included in the present review and highlighted
both elevated glutamate in the ACC and elevated Glx
in the putamen of clozapine responders as features of
treatment-resistance.
One possible mechanism underlying the efficacy of
clozapine in treatment-resistant illness may relate to its’
ability to attenuate glutamate release, as demonstrated
in several rat studies [54, 55]. The study of Demjaha et al.,
also reported lower concentrations of NAA, generally
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viewed as a marker of neuronal integrity, in the ACC of
treatment responsive compared to treatment-resistant
patients [18]; however, this finding has not been replicated
in other studies [20, 27].
Brain structure
Studies identified by this review find that treatment-
resistant patients have reduced grey matter volumes in
comparison to treatment-responsive patients [28, 29].
There is evidence for structural brain differences across
patients with schizophrenia [56, 57], but both of the
studies identified in the present review found that it was
only treatment-resistant patients that showed a signifi-
cant reduction in grey matter compared to healthy
volunteers; treatment-responsive patients showed no
significant differences in grey matter compared to
healthy volunteers. This suggests that abnormal reduc-
tions in grey matter may be specifically relevant to
treatment-resistant patients, and not an example of
simply more severe abnormalities. However, when
subdividing within treatment-resistant patients it ap-
pears that more severe reductions may be found in
ultra-treatment resistant patients [28] (though this
was not statistically significant).
Despite evidence that clozapine induces distinctive
structural changes in grey matter [58], one study
included treatment-resistant patients on clozapine while
the other did baseline imaging before their first dose of
clozapine, suggesting that this pattern should not imme-
diately be dismissed as secondary to clozapine treatment.
This pattern corroborates previous studies (not included
as they only look at response to a single antipsychotic
trial) which have found that smaller grey matter volume
is associated with poorer response to haloperidol [59]
and a prospective study in first-episode patients finding
reduced occipital grey matter predicted lack of response
[60].
These findings are consistent with the two other reviews
of treatment-resistant vs treatment-responsive patients
[48, 53] which identified studies demonstrating reduced
grey matter; however again, the 2015 review is more
cautious stating no consistent findings based on the two
they discuss, while the 2016 review identifies seven studies
and thus highlights reduced grey matter (particularly in
frontal regions) as one of the features of treatment-
resistance. The latter also suggest that these structural
differences could be caused by high concentrations of glu-
tamate, providing a plausible link between these findings
within the neuroimaging literature.
In contrast to our discussion above, Mouchlianitis et al.
conclude that grey matter abnormalities appears to be a
difference of degree along a continuum [48]; however, this
may be explained by their use of a much broader definition
of treatment-resistance and responsiveness. Perhaps
consistent treatment-responders show a distinct lack of
these abnormalities, but non-resistant patients (who may
later develop resistance, or show minimal response and fall
between the two groups of patients) show a reduction in
grey matter volume that falls along a continuum with
consistent treatment-resistant patients and ultra-treatment
resistant patients at the extremes.
Regarding white matter, Molina et al. [29] report that
increased occipital white matter at baseline was predictive
of subsequent treatment-resistance, which contrasts with
the null results reported in Anderson et al. [28] in patients
already taking clozapine. Mouchlianitis et all identify the
same two studies, noting that greater white matter is simi-
larly reported in the latter study but the difference be-
tween patient groups doesn’t reach significance [48]. One
possibility is that clozapine may work to normalise white
matter abnormalities, as studies have demonstrated reduc-
tions in white matter in patients taking clozapine [61].
Genes involved in neural development/growth
BDNF Studies in this review indicate that treatment-
resistant schizophrenia may be differentiated from
treatment-responsive schizophrenia by shorter alleles
of the dinucleotide repeat polymorphism [31], but
not the G196A (Val66Met) or C270T polymorphism
[30]. However, this finding did not survive multiple-
testing correction, this polymorphism had previously
been found to lack an association with schizophrenia
as a whole [62], and no other published studies look
at association with treatment-response.
The null result for Val66Met is somewhat surprising,
as two larger studies have found robust associations
when comparing clozapine users to non-clozapine users
(but not specifically confirmed treatment-responders, as
in this review) [63], and in a study looking at response
to a single antipsychotic trial [64]. This may reflect a
lack of power in the included study, or that the studies
are capturing different phenotypes.
Reelin Studies identified also suggest that treatment-
resistance may be differentiated from treatment-responsive
schizophrenia by greater repetition of the CCG repeat for
the 5’UTR polymorphism on the reelin gene [34]. However,
this was also not corrected for multiple-testing and this
polymorphism had previously been found to lack an associ-
ation with schizophrenia [65], despite reelin abnormalities
having long been associated with schizophrenia [66]; unfor-
tunately no other studies appear to look at an association
with treatment response.
Genetic loading
One study identified indicates that treatment-resistant
schizophrenia may be differentiated from treatment-
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responsive schizophrenia by higher familial loading scores
and greater risk of schizophrenia in relatives; in fact, the
study found that treatment-responsive patients did not
show the significantly higher risk compared to healthy
volunteers that treatment-resistant patients did [39]. An
earlier study looking at a single antipsychotic trial similarly
found that first-degree relatives of non-responders to
haloperidol had higher lifetime risk for schizophrenia
spectrum disorders [67]. More recent studies have found
associations between a history of clozapine treatment
and a higher polygenic risk score [68] and treatment-
resistance and higher genome-wide burden of rare
duplications [69] (but neither compared to confirmed
treatment-responders and were thus not included in
this review). These cumulatively suggest that treatment-
resistant schizophrenia may be more heritable, with stron-
ger genetic influence.
Immune system
One study identified indicates that treatment-resistance
may be differentiated from treatment-responsive schizo-
phrenia by predominance of the HLA-A1 allele [37] but
another found null results for a difference in HLA antigen
types [38].
Wider literature has indicated the importance of the im-
mune system in treatment-response, with two studies
finding that treatment-resistant patients show significantly
higher levels of serum IL-6 levels than healthy volunteers
(with non-resistant patients presenting with intermediate
levels) [70, 71] (neither were included in this review
because their non-resistant patients were not confirmed
as treatment-responsive). Similarly, two GWAS’s investi-
gating treatment response have also implicated variants
associated with the immune system: one compared
treatment-resistant patients to healthy volunteers and
found an association with polymorphisms of SLAMF1, a
gene associated with lymphocyte activation [72]; while
another looked at response to a single antipsychotic trial
and found an association with RTKN2, believed to be
involved in lymphopoiesis [73].
Neurocognitive function
Two papers identified indicate that treatment-resistant
patients have greater deficits in neurocognitive domains,
with a replicated result in verbal memory [42, 43]; this
would be consistent with previous studies that have long
reported associations between worsened memory and
treatment-resistance [74]. However, cross-sectional studies
suffer from symptom severity potentially confounding the
results.
Clinical variables
The one identified prospective study on PANSS scores re-
ported that a lower score at baseline predicted treatment-
resistance at 12 weeks, and found no association between
improvement in the first 2 weeks of antipsychotic treatment
and later treatment-response [40]. These are surprising
findings, especially the latter as a 2014 review of treatment
response (looking only at single-antipsychotic trials, and
thus not included in the review) found that early lack of re-
sponse was one of the most robust predictors of later lack
of response [75], and a 2015 meta-analysis (again looking at
only single-antipsychotic trials) found that lack of response
at two weeks had high specificity and positive predictive
validity for predicting later non-response [76]. It may be
that early lack of response predicts later non-response for
specific antipsychotics but not non-response in general (as
characterised by treatment-resistance); however, this seems
unlikely and it is much more plausible that the reported
lack of association in the present review is due to the small
sample size of the identified study.
One identified study indicated that treatment-resistance
is associated with an earlier age of onset [41], consistent
with multiple studies reporting that early age of onset is
predictive of poor outcomes [4, 77] and a review by Kessler
et al. [78] which reports that early age of onset is associated
with more severe, persistent and treatment-refractory con-
ditions across psychiatric disorders.
Demographic characteristics
The one identified study indicates a greater proportion
of white patients in treatment-resistant patient groups.
This finding has been replicated by another study [79]
(not included because it did not compare to confirmed
treatment-responsive patients) but the implications of
this are unclear. It has been fairly well-established that
the excess of schizophrenia in black African populations
typically seen is due to (as yet undetermined) non-
genetic factors [80], so these findings suggest that
treatment-resistant schizophrenia is less influenced by
these environmental factors; this would be consistent
with the above section suggesting increased heritability
in the treatment-resistant patient group. Similarly, a
large Danish epidemiological study [81] recently found
that established environmental risk factors for schizophre-
nia such as urban environment did not predict treatment-
resistance, and in fact were negatively correlated with
treatment-resistance.
Conclusions
Tentative evidence from a diverse range of research fields
supports the idea that treatment-resistance may be a
categorically distinct disorder; in contrast to treatment-
responsive schizophrenia, treatment-resistant schizophre-
nia appears to be characterised by a relatively normal
dopamine system but an abnormal glutamate system, and
significant decreases in grey matter. There is some
evidence indicating that treatment-resistant schizophrenia
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may be a broadly more genetic disorder, and differences
may be partially driven by different genotypic variants,
with explorative studies suggesting group differences in
genes involved in neurotransmission, immune function
and neural development; however, none of the gene-
association findings are reported to survive multiple
comparisons. Overall, there have been relatively few stud-
ies conducted comparing patients with strictly defined
treatment-resistance and treatment-responsiveness, and
there is little independent replication of significant
findings. In addition, definitions of treatment-resistance
and treatment-responsiveness remain inconsistent, and
confounding variables have often not been systematically
evaluated. Other reviews within the field highlight that
variable populations, heterogeneous definitions, under-
powered studies and the lack of prospective studies
(particularly from illness-onset) create challenges for
interpreting the literature [48].
Addressing the inconsistency of treatment-resistant defi-
nitions and the comparison groups used would be of great
value for future research, especially when attempting to
determine if there are categorical differences between
these groups of patients. We recommend that the field de-
velops and follows a consensus for more strictly defining
and referring to treatment-resistance, incorporating the
clinical guidelines as a minimum. This is underway with
the Treatment Response and Resistance in Psychosis
(TRRIP) Working Group, with guidelines in press [82]. In
addition, studies should carefully decide their comparison
groups and be very clear about whether it contains
patients who are simply non-resistant or who are demon-
strable treatment-responders; if the latter, they should be
clear about their definition of treatment-responders,
ideally aiming to use established consensus definitions for
response (e.g., Andreasen remission criteria [83]).
Future studies should also seek to both further replicate
the findings of glutamatergic and grey matter abnormal-
ities, and advance knowledge in areas where there are
contradictions or a simple lack of research. Investigating
neurochemical differences between treatment-responsive
and treatment-resistant patients may be of particular im-
portance, as these could inform different approaches to
pharmacological intervention. Neuroimaging studies may
also use resting state data to investigate functional
connectivity, as a recent study [84] and a review of the
broader literature [48] have indicated this may have a role
in predicting treatment response. In terms of genetic
markers of treatment-resistant illness, psychiatric genetics
as a field has moved away from the candidate-gene
approach used in all genetic studies identified by the
present review; future research should consider instead
well-powered GWAS’s and more sophisticated models in-
corporating gene-environment interactions and epigenetic
variation. Studies on social or environmental factors are
also notably lacking in the literature. Across these fields,
progressing from cross-sectional to prospective studies
will be required to firmly determine whether observed
differences are predictive of treatment response, or arise
consequential to differing antipsychotic treatment regi-
mens or duration of active symptoms. If future research
can confirm treatment-resistant schizophrenia as a dis-
tinct disorder from treatment-responsive schizophrenia, a
key next step towards personalised treatment will be then
determining whether predictors can be used to identify
treatment-resistance early in illness, and at an individual
patient level.
Endnotes
1Demjaha et al. (2014) used a subset of patients
reported in Demjaha et al. (2012). The 2012 paper re-
ported on dopamine synthesis capacity, and the 2014
reported on dopamine synthesis capacity and levels of
glutamate. Only the 2012 dopamine findings and 2014
glutamate findings are included in this review.
2Molina et al. [29] and de Bartolomeis et al. [43] also
measured PANSS scores but with cross-sectional designs
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